about
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFReduced vas deferens contraction and male infertility in mice lacking P2X1 receptorsB-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblastsThe intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayA critical function for B-Raf at multiple stages of myelopoiesisTracking genomic cancer evolution for precision medicine: the lung TRACERx studyLineage tracing of cardiac explant derived cells.A complex secretory program orchestrated by the inflammasome controls paracrine senescence.Analysis of the mammalian talin2 gene TLN2.BRAF inactivation drives aneuploidy by deregulating CRAFA-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression.Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.Characterization of novel markers of senescence and their prognostic potential in cancer.Talin 2 is a large and complex gene encoding multiple transcripts and protein isoformsOncogenic Braf induces melanocyte senescence and melanoma in mice.Recombination of 4p16 DNA markers in an unusual family with Huntington disease.Isolation and field-inversion gel electrophoresis analysis of DNA markers located close to the Huntington disease gene.Phosphorylations of Serines 21/9 in Glycogen Synthase Kinase 3α/β Are Not Required for Cell Lineage Commitment or WNT Signaling in the Normal Mouse IntestineThe cholesterol-binding protein NPC2 restrains recruitment of stromal macrophage-lineage cells to early-stage lung tumours.MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.Mouse models for BRAF-induced cancersExpression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts.Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720.Mechanisms of aneuploidy induction by RAS and RAF oncogenesRegulation of MEK/ERK pathway output by subcellular localization of B-Raf.Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes.Raf Kinases Are Essential for Phosphate Induction of ERK1/2 Phosphorylation in Hypertrophic Chondrocytes and Normal Endochondral Bone Development.Chromosome fragmentation by chromosome mediated gene transfer.Genetic analysis of the human Y chromosome by chromosome-mediated gene transfer.Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor.RalGDS is required for tumor formation in a model of skin carcinogenesis.cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells.ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf.Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinomaKRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment.CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation.Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a.Endothelial cell talin1 is essential for embryonic angiogenesis.Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer.
P50
Q24298749-E317E897-880C-4336-8ED6-7224C7E2D76CQ28505454-9164F0A6-1156-4961-BC87-70C959B1A4D0Q28508452-C9379576-2761-4B57-BD40-6C73BABC02A5Q28512744-048AA530-DCC7-4E34-8BAA-25837083A476Q28590150-BD943EDF-BA5E-41C9-8BD2-EC05994E117BQ28655985-EF3B885B-1C91-4D04-B396-DF1DDDA5A359Q33328467-0A4C72EA-4C81-4486-8279-913611E66D08Q34037190-1881E0A2-CDCB-441E-8ECE-4AA6E5CFDEEBQ34088569-C2B8B387-A2EE-40B9-B335-E1B89AF25A6AQ34286030-DAE08A8A-3235-4E58-8E86-08E5797DA86BQ34414124-BB70A341-4B75-43DD-B1C4-218516B32DEBQ34533804-42306021-CD03-4697-8AB5-73935B688933Q34662291-2B1DDE7D-552C-4334-8782-4B97D664C713Q34946043-1A22BE9F-99AA-482D-AA3D-167E5CDB4885Q34974162-E89E3952-A144-48E0-A0E0-3B0EE44F27B3Q35195406-F5D98EBE-729E-4272-BC7E-A6D4C9993BB8Q35265279-125A2F77-AEED-4C89-84BE-E17E8EB021B6Q36048048-952A7480-E828-4665-9C27-BCAAD87F1BA8Q36057569-A8353B65-1291-45B8-94B1-F12173ABC8B2Q36413436-38BD218B-17FE-49C6-B006-4BD4749B2CACQ36979850-C7D38CFC-7C35-4F22-8CA6-7F2A96219873Q37093107-C3AD4472-2E85-4987-A251-16D868C65EFFQ37407268-6815A6DB-DC25-4A8E-A2CC-2E4F79C9A3FBQ37948057-52E81984-58D6-45DF-B62C-674BCDBAA311Q37977165-89CFA5D0-EBA0-4BA0-8C8C-634DDE2D7CC9Q38292576-35F808CA-D45C-48A2-A4EA-524676E4010CQ39028324-A6A984AE-19C1-4CDC-9C21-D9CA560A609EQ39560337-26DBC255-2D3D-4E8F-869F-31FD3CA610FEQ39725208-FA6C4C04-1BFD-4DBD-A05A-53B2E4D3911BQ39980994-CAFD32F3-E670-4014-97CB-B3DF73334C78Q40447001-89DD96B4-77CD-48B9-B6F3-656F39D14DD3Q40699823-B5A3399A-C817-4D21-A5A2-C069AB2A4671Q40753319-890B6BE0-2233-4F2D-AA88-88803EB9B018Q40989877-197169D9-9E30-403C-BBA2-928B9DFEEF49Q41456624-7232CB79-0F8B-4C83-986F-50B4C18FEE8BQ41825679-9B10B555-6639-44E5-980D-B5E4B5967AA2Q41836780-C736E600-801B-4E9F-A392-8875593E2203Q42059658-0C95159A-BF8A-457D-91CA-8B5BE2005C4CQ42577942-ECC79C79-4C74-4C38-8C0B-E93B1A8FF9A5Q45901388-C320EA15-F774-469C-9CD3-9927F69F707C
P50
description
researcher ORCID ID = 0000-0003-1859-4487
@en
wetenschapper
@nl
name
Catrin Pritchard
@ast
Catrin Pritchard
@en
Catrin Pritchard
@es
Catrin Pritchard
@nl
type
label
Catrin Pritchard
@ast
Catrin Pritchard
@en
Catrin Pritchard
@es
Catrin Pritchard
@nl
prefLabel
Catrin Pritchard
@ast
Catrin Pritchard
@en
Catrin Pritchard
@es
Catrin Pritchard
@nl
P31
P496
0000-0003-1859-4487